Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 9/20 | 0.45 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 3/20 | 0.40 |
| ▸ | PRMT1 | Q99873 | 3/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | KDM4A | O75164 | 1/20 | 0.37 |
| ▸ | KDM4B | O94953 | 1/20 | 0.37 |
| ▸ | KDM5C | P41229 | 1/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14754363 | 0.85 | CA2 (0.41) | CHEK2CARM1PRMT1PARP1ESR1 | |
| SCHEMBL8220811 | 0.81 | HRH3 (0.48) | CHEK2CARM1PRMT1PARP1ADRB2 | |
| SCHEMBL1259158 | 0.81 | CARM1 (0.40) | CHEK2CARM1PRMT1PARP1ESR1 | |
| SCHEMBL8233552 | 0.81 | METAP2 (0.44) | CARM1PRMT1ESR1 | |
| SCHEMBL19268046 | 0.81 | CARM1 (0.40) | CHEK2CARM1PRMT1PARP1ESR1 | |
| SCHEMBL17440027 | 0.81 | CARM1 (0.40) | CHEK2CARM1PRMT1PARP1ESR1 | |
| Hydrochloric Acid SCHEMBL19260900 | 0.79 | CARM1 (0.41) | CHEK2CARM1PRMT1PARP1ESR1 | |
| SCHEMBL4542718 | 0.79 | PRKCI (0.53) | FYNKDM1A | |
| SCHEMBL31434769 | 0.78 | CHEK2 (0.49) | CHEK2PARP1ESR1KDM4AKDM4B | |
| SCHEMBL7863726 | 0.78 | ESR1 (0.41) | CHEK2CARM1PRMT1PARP1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040026-B2 | Muscarinic M1 receptor positive allosteric modulators | SUVEN LIFE SCIENCES LIMITED (IN) | 2021-06-22 | — | — | US | disclosed |
| CN-109952302-B | Positive allosteric modulators of muscarinic M1 receptors | 苏文生命科学有限公司 | 2020-11-24 | — | — | CN | disclosed |
| EP-3507289-B1 | MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LTD (IN) | 2020-07-15 | — | — | EP | disclosed |
| US-20190343812-A1 | MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2019-11-14 | — | — | US | disclosed |
| EP-3507289-A1 | MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Suven Life Sciences Limited (IN) | 2019-07-10 | — | — | EP | disclosed |
| CN-109952302-A | Muscarine M1 receptor forward direction allosteric modulators | 苏文生命科学有限公司 | 2019-06-28 | — | — | CN | disclosed |
| WO-2018042362-A1 | MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-03-08 | — | — | WO | disclosed |
| EP-2415763-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | UBE INDUSTRIES (JP) | 2016-01-27 | — | — | EP | disclosed |
| WO-2016009297-A1 | PYRIDINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | PFIZER INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| WO-2016009297-A1 | PYRIDINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | PFIZER INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| US-20160016907-A1 | PYRIDINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | PFIZER INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160016907-A1 | PYRIDINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | PFIZER INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160016907-A1 | PYRIDINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | PFIZER INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2014-04-24 | — | — | US | disclosed |
| US-8648097-B2 | Pyridylaminoacetic acid compound | UBE INDUSTRIES, LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | UBE INDUSTRIES, LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
| EP-2415763-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | Ube Industries, Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2264009-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | Ube Industries, Ltd. (JP) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040026-B2 | Muscarinic M1 receptor positive allosteric modulators | CHRM1, CHRM2, CHRM3 | FYN 2946/4885CHEK2 2102/4885CARM1 820/4885 |
| US-20190343812-A1 | MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, CHRM2, CHRM3 | FYN 2946/4885CHEK2 2102/4885CARM1 820/4885 |
| US-20160016907-A1 | PYRIDINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, CHRM2, CHRM4 | FYN 366/4885CHEK2 2768/4885CARM1 845/4885 |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | FYN 3794/4885CHEK2 4029/4885CARM1 3500/4885 |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | FYN 3718/4885CHEK2 3883/4885CARM1 3491/4885 |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | F12, C1S, AKR1C3 | FYN 2588/4885CHEK2 2963/4885CARM1 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.